622. Lymphomas: Translational Non-Genetic: Poster III

Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma

Evaluation and validation of automated multiplexed immunofluorescence for clinical lymphoma diagnoses

IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Lipid metabolic reprogramming mediated by YTHDF3 deficiency underlies immunotherapy resistance in extranodal NK/T-cell lymphoma

Radiomic features from PET-CT enable diagnostic and prognostic stratification in peripheral T-cell lymphoma

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX